These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12675208)

  • 41. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).
    Silva M; Poo J; Wagner F; Jackson M; Cutler D; Grace M; Bordens R; Cullen C; Harvey J; Laughlin M
    J Hepatol; 2006 Aug; 45(2):204-13. PubMed ID: 16780997
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hepatitis C virus treatment with pegylated interferon-alfa therapy leading to generalized interstitial granuloma annulare and review of the literature.
    Ahmad U; Li X; Sodeman T; Daboul I
    Am J Ther; 2013; 20(5):585-7. PubMed ID: 21317616
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pegylated interferons.
    Baker DE
    Rev Gastroenterol Disord; 2001; 1(2):87-99. PubMed ID: 12120178
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Interferon alfa-2a in the treatment of hepatitis C].
    Minerva Med; 2001 Jun; 92(3):XI-II. PubMed ID: 11503598
    [No Abstract]   [Full Text] [Related]  

  • 45. Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis.
    Everson GT; Balart L; Lee SS; Reindollar RW; Shiffman ML; Minuk GY; Pockros PJ; Govindarajan S; Lentz E; Heathcote EJ
    Aliment Pharmacol Ther; 2008 Apr; 27(7):542-51. PubMed ID: 18208570
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.
    Lindsay KL; Trepo C; Heintges T; Shiffman ML; Gordon SC; Hoefs JC; Schiff ER; Goodman ZD; Laughlin M; Yao R; Albrecht JK;
    Hepatology; 2001 Aug; 34(2):395-403. PubMed ID: 11481625
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interferon-alpha-2a. A review of its pharmacological properties and therapeutic use in the management of viral hepatitis.
    Haria M; Benfield P
    Drugs; 1995 Nov; 50(5):873-96. PubMed ID: 8586031
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Adverse effects of combining polyethylene glycol interferon with ribavilin on hepatitis C patients].
    Si CW
    Zhonghua Gan Zang Bing Za Zhi; 2003 Nov; 11(11):686-7. PubMed ID: 14636449
    [No Abstract]   [Full Text] [Related]  

  • 49. [Successful therapy with pegylated interferon alfa-2a. Hepatitis C patients remain virus-free].
    MMW Fortschr Med; 2003 Sep; 145(35-36):56. PubMed ID: 14584218
    [No Abstract]   [Full Text] [Related]  

  • 50. Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b.
    Venezia G; Licata A; Di Marco V; Craxì A; Almasio PL
    Dig Liver Dis; 2005 Nov; 37(11):882-5. PubMed ID: 16169301
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development of bronchiolitis obliterans organizing pneumonia during standard treatment of hepatitis C with Peg-IFNα2b.
    Chung E; Park K; Kim JH; Han NI; Lee YS; Bae SH; Park CH
    Korean J Intern Med; 2017 Nov; 32(6):1098-1100. PubMed ID: 28823117
    [No Abstract]   [Full Text] [Related]  

  • 52. Peginterferon alfa-2a (Pegasys) for chronic hepatitis C.
    Med Lett Drugs Ther; 2003 Mar; 45(1151):19-20. PubMed ID: 12612502
    [No Abstract]   [Full Text] [Related]  

  • 53. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.
    Bailon P; Palleroni A; Schaffer CA; Spence CL; Fung WJ; Porter JE; Ehrlich GK; Pan W; Xu ZX; Modi MW; Farid A; Berthold W; Graves M
    Bioconjug Chem; 2001; 12(2):195-202. PubMed ID: 11312680
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Methodological issues in a meta-analysis.
    Crémieux P
    Hepatology; 2010 Jul; 52(1):395-6; author reply 396-7. PubMed ID: 20583198
    [No Abstract]   [Full Text] [Related]  

  • 55. Fulminant type 1 diabetes caused by peginterferon α-2a therapy in hepatitis C.
    Zheng Y; Wang Z; Xie Z; Dai R; Zhou Z
    J Diabetes; 2018 May; 10(5):419-420. PubMed ID: 29265717
    [No Abstract]   [Full Text] [Related]  

  • 56. Interferon-alpha induced psoriasis in a teenager.
    Mendieta KL; Irfan M; Fernandez Faith E
    Pediatr Dermatol; 2018 Mar; 35(2):e136-e137. PubMed ID: 29575077
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reply to issues raised in the Jansen/Reesink editorial.
    Silva M
    J Hepatol; 2007 Feb; 46(2):350-1. PubMed ID: 17161883
    [No Abstract]   [Full Text] [Related]  

  • 58. [Systemic lupus erythematosus syndrome induced by interferon therapy].
    Martínez Alfaro E; Mateos Rodríguez F; Blanch Sancho JJ; Tárraga Rodríguez I
    Med Clin (Barc); 2004 Oct; 123(15):597. PubMed ID: 15535949
    [No Abstract]   [Full Text] [Related]  

  • 59. Effect of peginterferon alfa-2a (40KD) on cytochrome P450 isoenzyme activity.
    Brennan BJ; Xu ZX; Grippo JF
    Br J Clin Pharmacol; 2013 Feb; 75(2):497-506. PubMed ID: 22765278
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Focus on hepatitis. Weight-based versus fixed-dose peginterferons.
    Shaw-Stiffel T
    IAPAC Mon; 2004 May; 10(5):178-80. PubMed ID: 15366103
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.